DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection

Phase 3

Terminated

Conditions: Chronic Hepatitis B

Interventions: Drug: Entecavir + Tenofovir
Drug: Adefovir + continuing Lamivudine

First Posted Date: 2008-01-31

Last Posted Date: 2010-11-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 4

Registration Number: NCT00605384

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Kaiser Permanente Medical Center, San Francisco, California, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 1 locations

PoC in Rheumatoid Arthritis With Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis, NOS

Interventions: Drug: Placebo
Drug: BMS-582949

First Posted Date: 2008-01-31

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 121

Registration Number: NCT00605735

Locations: 🇺🇸
G. Timothy Kelly, Md, Las Vegas, Nevada, United States
🇨🇳
Local Institution, Taoyuan, Taiwan
🇺🇸
The Arthritis Group, Philadelphia, Pennsylvania, United States

and more 6 locations

Phase I/II Combination With Irinotecan- Erbitux

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer (MCRC)

Interventions: Drug: Cetuximab
Drug: Irinotecan
Drug: Brivanib
Drug: Brivanib Placebo

First Posted Date: 2008-01-16

Last Posted Date: 2015-11-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 38

Registration Number: NCT00594984

Locations: 🇺🇸
Usc/Norris Comprehensive Cancer Center Hospital, Los Angeles, California, United States
🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

and more 2 locations

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: MDX-1342

First Posted Date: 2008-01-15

Last Posted Date: 2013-05-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT00593944

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Oncology Consultants, PA, Houston, Texas, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Belatacept Pharmacokinetic Trial in Renal Transplantation

Phase 2

Completed

Conditions: Renal Transplantation

Interventions: Drug: Belatacept

First Posted Date: 2007-12-21

Last Posted Date: 2014-01-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 14

Registration Number: NCT00578448

Locations: 🇲🇽
Local Institution, Aguascalientes, Mexico
🇺🇸
Western New England Renal & Transplant, Springfield, Massachusetts, United States
🇺🇸
Henry Ford Hospital, Detriot, Michigan, United States

Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: EVRI (BMS-690514)

First Posted Date: 2007-12-21

Last Posted Date: 2008-07-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 17

Registration Number: NCT00578916

Locations: 🇨🇭
Local Institution, Allschwil, Switzerland

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

Phase 2

Completed

Conditions: Vascular Diseases

Interventions: Drug: Atorvastatin
Other: Placebo
Drug: BMS-582949
Drug: Statin

First Posted Date: 2007-12-11

Last Posted Date: 2015-12-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 72

Registration Number: NCT00570752

Locations: 🇺🇸
Florida Cardiovascular Institute, Tampa, Florida, United States
🇺🇸
Troy Internal Medince Pc/Research, Troy, Michigan, United States
🇺🇸
Baylor College Of Medicine, Houston, Texas, United States

and more 13 locations

Subcutaneous Pharmacokinetics of Belatacept

Phase 1

Completed

Conditions: Transplantation

Interventions: Drug: belatacept
Drug: Placebo

First Posted Date: 2007-12-07

Last Posted Date: 2016-09-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 153

Registration Number: NCT00569803

Locations: 🇺🇸
Ppd Development, Austin, Texas, United States

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Neoplasms
Solid Tumors
Metastases

Interventions: Drug: BMS-754807

First Posted Date: 2007-12-06

Last Posted Date: 2013-08-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 63

Registration Number: NCT00569036

Locations: 🇦🇺
Local Institution, Nedlands, Western Australia, Australia

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Dasatinib
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2007-11-19

Last Posted Date: 2017-03-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT00560352

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States
🇪🇸
Local Institution, Salamanca, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy